share_log

Cannabis Boom Or Bust: State Trends Marijuana Investors Can't Afford To Ignore In 2Q24

Cannabis Boom Or Bust: State Trends Marijuana Investors Can't Afford To Ignore In 2Q24

大麻股繁榮還是崩盤:州趨勢是大麻投資者在 2Q24 不能忽視的
Benzinga ·  08/06 21:46

Quarterly earnings will highlight efficient operators' growing market share and building sustainable platforms. Pablo Zuanic, senior analyst at Zuanic & Associates, provides an overview of the cannabis market trends in key states ahead of the second quarter earnings season.

季度收益將突顯高效運營商不斷增長的市場份額和構建可持續平台。Zuanic&Associates高級分析師Pablo Zuanic概述了大麻市場在二季度收益季節到來之前在主要州的趨勢。

Zuanic emphasizes that federal reform expectations, IRS news on 280E, refinancing potential and M&A strategies will be the main drivers of sentiment.

Zuanic強調聯邦改革期望、稅收局對280E的新聞、再融資潛力和併購策略將是情緒的主要推動者。

State Performance Highlights

州的業績亮點

  • Florida: Despite a slowing pace and price deflation, Florida's medical marijuana sales reached $479 million in 2Q24, with a slight decrease of 2% quarter-over-quarter (QoQ). Trulieve (OTC:TCNNF) remains the leader with 142 stores, followed by Verano (OTC:VRNOF) with 77 stores.

  • Illinois: Sales grew to $505 million in 2Q24, a 2% QoQ increase, though the market underperforms with $158 per capita spent compared to Michigan's $333. Ascend (OTC:AAWH), Curaleaf (OTC:CURLF), Verano, Cresco (OTC:CRLBF) and Green Thumb (OTC:GTBIF) each have 10 stores in the state.

  • Pennsylvania: Robust growth continues with 2Q24 sales at $426 million, up 11% year-over-year. The state boasts healthy retailer economics with annualized revenue per store at $9.4 million. Verano leads with 18 stores.

  • Arizona: Sales declined 7% QoQ to $301 million in 2Q24, with ongoing deflation impacting both growers and retailers. Trulieve and Curaleaf lead with 21 and 16 stores, respectively.

  • Maryland: With recreational sales starting on 7/1/23, total sales reached $284 million in 2Q24, up 130% YoY. Curaleaf and Green Thumb are significant players in the state with multiple stores each.

  • New Jersey: Although growing, New Jersey lags in per capita spending with sales totaling $225 million in 1Q24. Curaleaf, Verano, and Green Thumb have a notable presence with multiple operational stores.

  • Ohio: Medical marijuana sales remained flat at $120 million in 2Q24, but prices are rising as retailers begin recreational sales. Cresco, Green Thumb, and Columbia Care (OTC:CCHWF) are key operators in the state.

  • Michigan: The state continues to see strong growth with 2Q24 sales at $837 million, up 6% QoQ and 11% YoY. Michigan leads in per capita spending with $333. Green Peak Innovations and Lume Cannabis Co. are significant players with extensive store networks.

  • 佛羅里達:儘管速度放緩和價格走低,佛羅里達的醫用大麻銷售額在第二季度達到4.79億美元,環比下降2%。Trulieve(OTC:TCNNF)仍然是領先者,擁有142家商店,其次是Verano(OTC:VRNOF)擁有77家商店。

  • 伊利諾伊州:2Q24銷售額增長2%,達到5.05億美元,儘管市場表現不佳,人均花費158美元,低於密歇根州的333美元。Ascend(OTC:AAWH)、Curaleaf(OTC:CURLF)、Verano、Cresco(OTC:CRLBF)和Green Thumb(OTC:GTBIF)在該州各有10家商店。

  • 賓夕法尼亞州:穩健的增長仍在繼續,2Q24的銷售額達到4.26億美元,同比增長11%。該州擁有良好的零售商經濟,每家商店的年收入爲940萬美元。Verano領先,擁有18家商店。

  • 亞利桑那州:2Q24銷售額環比下降7%,達到3.01億美元,持續的通貨緊縮影響了種植者和零售商。Trulieve和Curaleaf分別擁有21和16家商店領先。

  • 馬里蘭州:在2023年7月1日開始銷售娛樂用大麻後,總銷售額在2Q24達到了2.84億美元,同比增長130%。Curaleaf和Green Thumb是該州的重要參與者,各自擁有多家商店。

  • 新澤西州:儘管有所增長,但新澤西州的人均支出相對較低,銷售額爲2.25億美元,在1Q24。Curaleaf、Verano和Green Thumb在該州擁有多家運營商。

  • 俄亥俄州:醫用大麻的銷售額保持不變,爲1.2億美元,但隨着零售商開始銷售娛樂用大麻,價格正在上漲。Cresco、Green Thumb和Columbia Care(OTC:CCHWF)是該州的主要運營商。

  • 密歇根州:該州繼續保持強勁增長,在2Q24銷售額達到8.37億美元,環比增長6%,同比增長11%。密歇根州以人均支出333美元的表現領先。Green Peak Innovations和Lume Cannabis Co.是重要的參與者,擁有廣泛的商店網絡。

These issues will be among the hot topics at the upcoming Benzinga Cannabis Capital Conference in Chicago this Oct. 8-9. Join us to get more insight into what the wave of weed legalization means for the future of investing in the industry. Hear directly from top executives, investors, advocates, and policymakers. Get your tickets now before prices go up by following this link.

這些問題將是即將到來的芝加哥Benzinga大麻資本會議的熱門話題,時間是10月8日至9日。加入我們,以獲取關於大麻合法化浪潮對該行業投資未來意味着什麼的更深入了解。直接聽取高管,投資者,倡導者和政策制定者的意見。在通過此鏈接購買門票之前,抓緊時間,因爲價格會上漲。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論